Zhi Ling Teo

机构：The University of Melbourne, Peter MacCallum Cancer Centre · ORCID：0000-0002-0748-0858

发表论文 68 篇 · 总被引 4434 次 · h-index 19

代表论文

• Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer (2023 · npj Breast Cancer · 被引 27)
• Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer (2023 · JNCI Journal of the National Cancer Institute · 被引 17)
• Figure S3 from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade (2023 · 被引 1)
• Supplementary Figure 1 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers (2023)
• Supplementary Table 2 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers (2023)
• Supplementary Table 1 from Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers (2023)